Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 20/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 13/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10086858 | 1.00 | PTGFR (0.57) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL3368587 | 1.00 | PTGFR (0.57) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL3368578 | 1.00 | PTGFR (0.57) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL6128022 | 1.00 | PTGFR (0.57) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL13143407 | 1.00 | PTGFR (0.57) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL20016570 | 1.00 | PTGFR (0.57) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL13876584 | 0.91 | PTGFR (0.46) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL21754429 | 0.90 | PTGFR (0.53) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL19409783 | 0.89 | PTGFR (0.45) | PTGFRPTGER1PTGER2PTGER3TBXA2R | |
| SCHEMBL20016565 | 0.89 | PTGFR (0.53) | PTGFRPTGER1PTGER2PTGER3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094779-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTICS AGENTS | NOVAER HOLDINGS INC (US) | 2023-03-30 | — | — | US | claimed |
| US-20130142858-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTIC AGENTS | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-4218759-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230094779-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTICS AGENTS | NOVAER HOLDINGS INC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3811943-B1 | COMPOUND FOR USE IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20210251892-A1 | IMPLANTABLE DEVICE FOR DELIVERY OF THERAPEUTIC SUBSTANCES TO THE EYE | NOVAER HOLDINGS INC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3461484-B9 | DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3811943-A1 | COMPOUND FOR USE IN THE TREATMENT OF OCULAR DISORDERS | Aerie Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10869833-B2 | Drug delivery devices for delivery of ocular therapeutic agents | NOVAER HOLDINGS INC (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3461484-B1 | DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10588901-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-9415043-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160106667-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTIC AGENTS | KOPCZYNSKI CASEY (US) | 2016-04-21 | — | — | US | disclosed |
| US-20140275160-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275161-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8765166-B2 | Drug delivery devices for delivery of ocular therapeutic agents | NOVAER HOLDINGS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130317458-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTIC AGENTS | AERIE PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130142858-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTIC AGENTS | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2010080622-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS | AERIE PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100158980-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS | NOVAER HOLDINGS, INC. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251892-A1 | IMPLANTABLE DEVICE FOR DELIVERY OF THERAPEUTIC SUBSTANCES TO THE EYE | STRA6, SLC47A1, PGF | PTGFR 20/4885PTGER1 959/4885PTGER2 1177/4885 |
| US-10869833-B2 | Drug delivery devices for delivery of ocular therapeutic agents | STRA6, SLC47A1, SLC47A2 | PTGFR 46/4885PTGER1 554/4885PTGER2 768/4885 |
| US-20130142858-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTIC AGENTS | STRA6, SLC47A1, SLC47A2 | PTGFR 46/4885PTGER1 554/4885PTGER2 768/4885 |
| US-20230094779-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTICS AGENTS | STRA6, SLC47A1, FLT1 | PTGFR 48/4885PTGER1 571/4885PTGER2 842/4885 |
| US-20140275160-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | PTGFR 12/4885PTGER1 5/4885PTGER2 8/4885 |
| US-10588901-B2 | Combination therapy | PTGS1, PTGS2, PTGIS | PTGFR 12/4885PTGER1 5/4885PTGER2 8/4885 |
| US-20160106667-A1 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTIC AGENTS | STRA6, SLC47A1, SLC47A2 | PTGFR 46/4885PTGER1 554/4885PTGER2 768/4885 |
| US-20140275161-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | PTGFR 12/4885PTGER1 5/4885PTGER2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.